Navigation Links
Evotec Reports Third Quarter 2007 Results
Date:11/13/2007

Evotec AG (Frankfurt Stock Exchange: EVT) Reported Today Results for the First Nine Months of 2007.

HAMBURG, Germany and OXFORD, England, November 13 /PRNewswire-FirstCall/ --

Highlights:

- Financials in-line with Evotec's full year expectations

- Compelling results achieved in two proof-of-concept Phase II trials with lead insomnia drug candidate EVT 201

- Sale of the Chemical Development Business to Aptuit and the proposed Renovis acquisition further emphasize the strategic transformation of Evotec towards a drug discovery and development company

- Merger will create a global company with three clinical candidates, a strong late stage preclinical pipeline focusing on areas of neurological and inflammatory diseases, and a strong cash position; expected to close in Q1 2008

- Expected year-end cash position increased to EUR 93-98 million, not yet including Renovis' cash

All amounts discussed in this press release are related to Evotec's continuing operations. The discontinued operations and a discussion of the business sold to Aptuit are provided in Evotec's full Third Quarter Report.

Revenues for the first nine months of 2007 were EUR 23.2 million, 23% below last year's level (2006: EUR 29.9 million). The decline is the consequence of (i) lower milestone income compared to the same period last year (approximately - EUR 3 million), (ii) the reduction of the library synthesis business following the transfer of this business into a joint venture with RSIL (reduction of EUR 4.0 million or 82%), and (iii) decline of the US dollar against Evotec's reporting currency Euro. At constant 2006 currencies (UK Sterling and US dollar), revenues would have been approximately one million higher (EUR 24.1 million). Excluding these three extraordinary effects Evotec's remaining business performed strongly, growing 6% from EUR 21.9 million for the first nine months of 2006 to EUR 23.2 million for the first nine months 2007.<
'/>"/>

SOURCE Evotec AG
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
2. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
3. Evotec to Present at the UBS 2007 Global Life Sciences Conference in New York
4. Evotec AG: R&D Update on 16 October 2007 Live on the Internet
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. QMed, Inc. Reports July Medicare SNP Enrollments
7. Phlo Affiliate Reports Expanded Coverage to Oregon Border
8. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
9. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
10. Carrington Reports Second Quarter 2007 Results
11. Avitar Reports Third Quarter Financial Results for Fiscal 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... Dennis R. HIll M.D. Radiation Oncologist at the ... recently there has been a promotion of the idea that ... seed, or low dose rate, brachytherapy for prostate cancer. The ... a shorter half life, and gives a higher biologically effective ... has a higher average energy than the other commonly used ...
(Date:5/24/2013)... 24, 2013 Senomyx , Inc. (NASDAQ: ... science technologies to discover, develop, and commercialize novel flavor ... , Ph.D., the Company,s Vice President, Biology and ... & Corporate Communications, will present an overview of Senomyx,s ... a.m. Eastern Time (7:25 a.m. Pacific Time) during the ...
(Date:5/24/2013)... Madison, WI (PRWEB) May 24, 2013 ... to the discovery and development of calcium-binding proteins ... publication of safety assessment study of apoaequorin ... an international journal published for the British Industrial ... the study was to investigate potential adverse effects, ...
(Date:5/23/2013)... Can economic incentives such as gift ... of the public to increase their donations of blood? ... Carey Business School Assistant Professor Mario Macis says ... large body of recent research that supports their argument, ... issue of Science that the World Health Organization and ...
Breaking Biology Technology:Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same 2Dennis R. Hill MD HDR Prostate Brachytherapy Specialist Compares Prostate Cancer Treatment Options: Not All Low Dose Rate Brachytherapy Isotopes Are the Same 3SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3
... Feb. 9 Celsis In Vitro Technologies (Celsis,IVT), ... life science,products and laboratory services company, and Wisconsin-based ... of ADME-Tox testing in primary,hepatocytes. Celsis IVT ... use with Promega,s bioluminescent ADME-Tox assays, including,the P450-Glo(TM) ...
... of Pharmaceuticals in a New U.S. Political AdministrationPHILADELPHIA, ... start of the first annual conference on Managed ... at the Loews Philadelphia Hotel. The conference ... needed to prepare for future changes in health ...
... Measuring Prevalence of Sleep Apnea Among Insomnia PatientsALBUQUERQUE, N.M., ... (SHHI) was awarded a grant to study one of ... connects insomnia to psychological factors -- stress, racing thoughts, ... pills or talk therapy. Pitted against the CW ...
Cached Biology Technology:Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 2Celsis In Vitro Technologies and Promega to Offer Fast, Reliable Solutions for ADME-Tox Testing With Primary Hepatocytes 3ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference 2ExL Pharma Presents The Pharmaceutical Managed Markets Insight & Marketing for the Pharmaceutical Industry Conference 3Controversial Study to Test Link Between Insomnia and Sleep Apnea 2
(Date:5/23/2013)... Pacific Northwest National Laboratory honored more than 165 ... intellectual property at PNNL,s annual Intellectual Property Commercialization ... Department of Energy national laboratory named materials scientist ... work developing battery materials that can store large ... grid, and reduce the time it takes to ...
(Date:5/23/2013)... The tight wrapping of genomic DNA around nucleosomes ... gene expression. A team of Ludwig-Maximilians-Universitaet (LMU) in ... DNA to be locally displaced from nucleosomes for ... is stored in the cell nucleus, wrapped around ... pairs of four different histone proteins and accommodating ...
(Date:5/23/2013)... have succeeded in treating cerebral palsy with autologous cord ... a 2.5 year old boy had been in a ... Just two months after treatment with the cord blood ... following months, the child learned to speak simple sentences ... a Korean study, dispel the long-held doubts about the ...
Breaking Biology News(10 mins):PNNL staff recognized for scientific accomplishments, moving technologies into the marketplace 2Biochemistry: Unspooling DNA from nucleosomal disks 2First successful treatment of pediatric cerebral palsy with autologous cord blood 2
... inventions are birthed at a bar, their futures scribbled ... technological change in X-rays in more than a century, ... It was 2000. Otto Zhou was the principal investigator ... Naval Research to find applications for carbon nanotubes. Zhou ...
... atmospheric mercury emissions should quickly reduce mercury levels in ... week in the Proceedings of the National Academy of ... loading at rates relevant to atmospheric deposition resulted in ... fish in only three years. This is ...
... and ... terminal solutions, WALL, N.J., Sept. 18 ... in finger-based biometric,identification and wireless public safety solutions, ... technology to the hospitality and,retail industries, announced today ...
Cached Biology News:UNC nanotech spin-off forms new venture with Siemens 2UNC nanotech spin-off forms new venture with Siemens 3New study shows fish respond quickly to changes in mercury deposition 2New study shows fish respond quickly to changes in mercury deposition 3Radiant Systems Selects BIO-key(R) Biometric Software for POS Solution 2Radiant Systems Selects BIO-key(R) Biometric Software for POS Solution 3
...
BD Primaria 35 mm Cell Culture Dish with Easy-Grip design, surface-modified polystyrene for enhanced cell culture. (20/sp, 200/ca) Packaging: 20 / sleeve, 500 / case ...
...
BD Falcon insert HTS 96 well, square A-bottom with lid. PET membrane, sterile. (5/ca) Packaging: 5 / pack, 5 / case ...
Biology Products: